Drug Profile
Research programme: PEGylated peptide therapeutics - Zealand Pharma/PolyTherics
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator PolyTherics; Zealand Pharma
- Class Peptides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Metabolic disorders
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Metabolic-disorders in Denmark (Parenteral)
- 16 Jul 2016 No recent reports of development identified for research development in Metabolic-disorders in United Kingdom (Parenteral)
- 04 Mar 2010 Early research in Metabolic disorders in Denmark (Parenteral)